CY1118184T1 - Μεθοδοι συνθεσης και/ή καθαρισμου ενωσεων διαμινοφαινοθειαζινιου - Google Patents
Μεθοδοι συνθεσης και/ή καθαρισμου ενωσεων διαμινοφαινοθειαζινιουInfo
- Publication number
- CY1118184T1 CY1118184T1 CY20161101128T CY161101128T CY1118184T1 CY 1118184 T1 CY1118184 T1 CY 1118184T1 CY 20161101128 T CY20161101128 T CY 20161101128T CY 161101128 T CY161101128 T CY 161101128T CY 1118184 T1 CY1118184 T1 CY 1118184T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disease
- infection
- methods
- compounds
- dementia
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000004140 cleaning Methods 0.000 title 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 201000002832 Lewy body dementia Diseases 0.000 abstract 2
- 102100040243 Microtubule-associated protein tau Human genes 0.000 abstract 2
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 2
- 206010034010 Parkinsonism Diseases 0.000 abstract 2
- 206010057293 West Nile viral infection Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 abstract 1
- 206010002027 Amyotrophy Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 208000010362 Protozoan Infections Diseases 0.000 abstract 1
- 102000019355 Synuclein Human genes 0.000 abstract 1
- 108050006783 Synuclein Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 abstract 1
- 241000710886 West Nile virus Species 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 208000030381 cutaneous melanoma Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- -1 diaminophenothiazine compounds Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000005135 methemoglobinemia Diseases 0.000 abstract 1
- 229960000907 methylthioninium chloride Drugs 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 208000021090 palsy Diseases 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000009256 peri post natal development Effects 0.000 abstract 1
- 210000004910 pleural fluid Anatomy 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 210000003523 substantia nigra Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B21/00—Thiazine dyes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0096—Purification; Precipitation; Filtration
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0097—Dye preparations of special physical nature; Tablets, films, extrusion, microcapsules, sheets, pads, bags with dyes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Η εφεύρεση αυτή σχετίζεται γενικά με το πεδίο της χημικής σύνθεσης και καθαρισμού, και ειδικότερα με μεθόδους σύνθεσης και/ή καθαρισμού ορισμένων ενώσεων του 3,7 διαμινο-φαινοθειαζιν-5-ίου (αναφερόμενες στο παρόν ως «ενώσεις διαμινοφαινοθειαζινίου») περιλαμβάνοντας Χλωριούχο Μεθυλοθειονίνιο (MTC) (επίσης γνωστό ως Μπλε του Μεθυλενίου). Η παρούσα εφεύρεση επίσης σχετίζεται με τις προκύπτουσες (υψηλής καθαρότητας) ενώσεις, συνθέσεις οι οποίες τις περιλαμβάνουν (π.χ., δισκία, κάψουλες), και τη χρήση τους σε μεθόδους εξουδετέρωσης παθογόνων, και μεθόδους ιατρικής αντιμετώπισης, προφύλαξης και διάγνωσης, κλπ., για παράδειγμα, μιας ταυπάθειας˙ μιας νόσου συσσώρευσης της tau πρωτεΐνης˙ νόσου Alzheimer (AD)˙ νόσου Pick˙ Προϊούσας Υπερπυρηνικής Παράλυσης (PSP)˙ μετωποκροταφικής άνοιας (FTD)˙ FTD και παρκινσονισμού σχετιζόμενου με το χρωμόσωμα 17 (FTDP-17)˙ συμπλέγματος άρσεως αναστολών-άνοιας-παρκινσονισμού-αμυοτροφίας (DDPAC)˙ εκφύλισης της ωχράς σφαίρας, της γέφυρας, της μέλαινας ουσίας (PPND)˙ Guam-ALS συνδρόμου˙ εκφύλισης της ωχράς σφαίρας, της μέλαινας ουσίας, του σωματίου του Luys (PNLD)˙ φλοιοβασικής εκφύλισης (CBD)˙ ήπιας γνωστικής βλάβης (MCI)˙ καρκίνου του δέρματος˙ μελανώματος˙ μεθαιμοσφαιριναιμίας˙ μιας ιικής μόλυνσης˙ μιας βακτηριακής μόλυνσης˙ μιας πρωτοζωικής μόλυνσης˙ μιας παρασιτικής μόλυνσης˙ ελονοσίας˙ σπλαγχνικής λεϊσμανίασης˙ Αφρικανικής ασθένειας ύπνου˙ τοξοπλάσμωσης˙ γιαρδίασης˙ νόσου του Chagas˙ μόλυνσης από ιό Ηπατίτιδας C (HCV)˙ μόλυνσης από ιό ανθρώπινης ανοσοανεπάρκειας (HIV)˙ μόλυνσης από ιό του Δυτικού Νείλου (WNV)˙ μιας συνουκλεϊνοπάθειας˙ νόσου Parkinson (PD)˙ άνοιας με σωμάτια Lewy (DLB)˙ ατροφίας πολλαπλών συστημάτων (MSA)˙ επαγόμενου από φάρμακα παρκινσονισμού˙ και ανεπάρκειας του αυτόνομου (PAF).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81962706P | 2006-07-11 | 2006-07-11 | |
| EP07733509.9A EP2057136B1 (en) | 2006-07-11 | 2007-07-10 | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118184T1 true CY1118184T1 (el) | 2017-06-28 |
Family
ID=38669650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101128T CY1118184T1 (el) | 2006-07-11 | 2016-11-03 | Μεθοδοι συνθεσης και/ή καθαρισμου ενωσεων διαμινοφαινοθειαζινιου |
Country Status (16)
| Country | Link |
|---|---|
| US (10) | US7956183B2 (el) |
| EP (5) | EP2057136B1 (el) |
| JP (2) | JP5350237B2 (el) |
| CN (2) | CN101511803B (el) |
| AU (1) | AU2007274057B2 (el) |
| CA (1) | CA2657352C (el) |
| CY (1) | CY1118184T1 (el) |
| DK (4) | DK3121169T3 (el) |
| ES (4) | ES2421930T3 (el) |
| HU (1) | HUE030621T2 (el) |
| LT (1) | LT2457905T (el) |
| MY (2) | MY148145A (el) |
| PL (4) | PL2457905T3 (el) |
| PT (4) | PT2457904E (el) |
| SI (4) | SI2057136T1 (el) |
| WO (1) | WO2008007074A2 (el) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1799662T1 (sl) | 2004-09-23 | 2013-08-30 | Wista Laboratories Ltd. | Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC) |
| CN104529939B (zh) | 2006-03-29 | 2019-05-07 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| DK3121169T3 (da) | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| ES2739546T3 (es) * | 2007-06-19 | 2020-01-31 | Wista Lab Ltd | Compuestos de fenotiazina para tratar el deterioro cognitivo leve |
| SI2205245T1 (sl) | 2007-10-03 | 2015-10-30 | Wista Laboratories Ltd. | Terapevtska uporaba diaminofenotiazinov |
| MX2011005979A (es) * | 2008-12-09 | 2011-06-27 | Interquim Sa | Procedimiento de obtencion de (6s)-(-)-5,6,7,8-tetrahidro-6-[propi l-(2-tienil)etil]amino-1-naftol(rotigotina). |
| EP2585073B1 (en) | 2010-04-30 | 2016-04-27 | Prosetta Antiviral Inc. | Antiviral compounds |
| US8828986B2 (en) | 2011-04-20 | 2014-09-09 | Prosetta Antiviral Inc. | Antiviral compounds |
| DE102010062810B4 (de) * | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
| WO2012107706A1 (en) | 2011-02-11 | 2012-08-16 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| RU2535073C1 (ru) * | 2013-07-18 | 2014-12-10 | Федеральное государственное бюджетное учреждение науки "Научно-исследовательский институт общей реаниматологии имени В.А. Неговского" Российской академии медицинских наук | Способ лечения метгемоглобинемии |
| BR112016002979A8 (pt) * | 2013-08-15 | 2020-02-04 | Eupharma Pty Ltd | processo para a purificação de um composto de diaminofenotiazínio, processo para a purificação de azul de metileno e uso de um complexo de diaminofenotiazínio estabilizado protonado |
| GB201317702D0 (en) * | 2013-10-07 | 2013-11-20 | Wista Lab Ltd | Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| FR3015481B1 (fr) * | 2013-12-20 | 2016-08-12 | Etat Francais Represente Par Le Delegue General Pour L'armement | Utilisation de composes de diaminophenothiazinium en tant qu'agents de prevention, reduction ou suppression d'une radiotoxicite |
| CN103864717B (zh) * | 2014-04-04 | 2015-11-11 | 山东理工大学 | 一种针状亚甲基白晶体的制备方法 |
| WO2016133959A1 (en) | 2015-02-17 | 2016-08-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| AU2016220096B2 (en) | 2015-02-17 | 2020-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
| GB201512678D0 (en) * | 2015-07-20 | 2015-08-26 | Wista Lab Ltd | Methods of chemical synthesis |
| CN105399703B (zh) * | 2015-12-15 | 2018-02-13 | 江苏恒润制药有限公司 | 一种亚甲基蓝的制备方法 |
| CN105541756B (zh) * | 2015-12-17 | 2018-02-09 | 陕西方舟制药有限公司 | 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法 |
| ITUA20163526A1 (it) | 2016-05-17 | 2017-11-17 | Icrom Spa | Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza |
| SG11201900228YA (en) | 2016-07-25 | 2019-02-27 | Wista Lab Ltd | Administration and dosage of diaminophenothiazines |
| US10745366B2 (en) | 2016-08-25 | 2020-08-18 | Arizon Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| WO2018039077A1 (en) | 2016-08-25 | 2018-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| US11413240B2 (en) | 2016-12-29 | 2022-08-16 | Board Of Regents, The University Of Texas System | Methylene blue solution for the treatment of oral lesions |
| WO2018132320A1 (en) * | 2017-01-10 | 2018-07-19 | The Texas A&M University System | Methanesulfonic acid mediated solvent free synthesis of conjugated porous polymer networks |
| FR3063495B1 (fr) * | 2017-03-02 | 2019-04-05 | Provepharm Life Solutions | Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium |
| EP3375777A1 (en) | 2017-03-15 | 2018-09-19 | MIKROCHEM spol. s.r.o. | Method for preparation of 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride or bromide |
| MX2021000894A (es) | 2018-07-26 | 2021-03-31 | Wista Lab Ltd | Dosificacion optimizada de diaminofenotiazinas en poblaciones. |
| US11350853B2 (en) | 2018-10-02 | 2022-06-07 | Under Armour, Inc. | Gait coaching in fitness tracking systems |
| CN109337681B (zh) * | 2018-11-22 | 2020-05-08 | 南京工业大学 | 一种硫氮共掺杂的碳量子点的制备方法和应用 |
| TR201818670A2 (tr) | 2018-12-05 | 2020-06-22 | Eti Gida Sanayi Ve Ticaret Anonim Sirketi | Sızıntı yapmayan gıda dolgu maddesi depozitör sistemi. |
| US12215234B2 (en) * | 2019-09-21 | 2025-02-04 | RK Pharma Solutions LLC | Process for the purification of methylene blue |
| CA3169480A1 (en) * | 2020-02-28 | 2021-09-02 | Janmejay R. VYAS | A process for the preparation of methylene blue |
| US12280062B2 (en) | 2021-02-24 | 2025-04-22 | Zydus Lifesciences Limited | Parenteral compositions comprising methylene blue |
| CN114806211B (zh) * | 2022-03-16 | 2023-04-07 | 深圳先进技术研究院 | 一种疏水性亚甲蓝荧光染料及其制备方法和应用 |
| CN114656424B (zh) * | 2022-03-16 | 2023-06-27 | 深圳先进技术研究院 | 一种上转换长余辉化学发光成像纳米探针及其制备方法和应用 |
| CN116947783A (zh) * | 2022-04-19 | 2023-10-27 | 英科隆生物技术（杭州）有限公司 | 一种电子媒介体的提纯方法 |
| CN114507193B (zh) * | 2022-04-19 | 2022-06-24 | 英科隆生物技术（杭州）有限公司 | 电子媒介体天青c的提纯方法 |
| WO2023202464A1 (zh) * | 2022-04-19 | 2023-10-26 | 英科隆生物技术（杭州）有限公司 | 一种电子媒介体的提纯方法 |
| EP4531863A1 (en) | 2022-05-31 | 2025-04-09 | WisTa Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| CN114989113A (zh) * | 2022-06-01 | 2022-09-02 | 山东科源制药股份有限公司 | 一种药用亚甲基蓝的精制方法 |
| WO2024061971A1 (en) | 2022-09-21 | 2024-03-28 | Wista Laboratories Ltd. | Novel formulations and vehicles |
| US20240115579A1 (en) | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| EP4342451A1 (en) | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| CN117447421A (zh) * | 2023-10-30 | 2024-01-26 | 上海沃凯生物技术有限公司 | 一种3,7-双-（二甲胺基）-吩噻嗪的合成方法 |
| CN119823064B (zh) * | 2025-01-03 | 2025-12-30 | 仁合益康集团有限公司 | 一种亚甲蓝的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1886C (de) | 1877-12-15 | 1877-12-15 | Basf Ag | Verfahren zur darstellung blauer farbstoffe aus dimethylanilin und anderen tertiaeren aromatischen monaminen |
| DE103147C (de) * | 1898-06-07 | 1899-04-05 | Cohn Georg | Verfahren zur darstellung von acetylleukomethylenblau und -äthylenblau. |
| DE113721C (de) * | 1899-06-01 | 1900-09-28 | Verfahren zur Darstellung von Acidylderivaten der Leukothioninfarbstoffe | |
| US3395018A (en) * | 1964-04-29 | 1968-07-30 | Du Pont | Light-sensitive color-forming composition |
| US3641016A (en) * | 1968-02-16 | 1972-02-08 | Egyt Gyogyszervegyeszeti Gyar | Thionine derivatives |
| DE2515966C3 (de) | 1975-04-11 | 1979-11-22 | Boehringer Mannheim Gmbh, 6800 Mannheim | Vorgefärbte Objektträger für die Blutunte rsuchung |
| US4003892A (en) | 1975-04-17 | 1977-01-18 | Serva-Entwicklungslabor V. Grothe & Co. | Method of separating thionine and its N-methyl derivatives from each other |
| US4212971A (en) | 1979-03-08 | 1980-07-15 | American Cyanamid Company | Process for preparing methylene blue |
| JPS6385644A (ja) * | 1986-09-30 | 1988-04-16 | Ricoh Co Ltd | 電子写真現像剤用トナ− |
| US5344928A (en) | 1991-04-26 | 1994-09-06 | Takeda Chemical Industries, Ltd. | Phenothiazine derivatives, their production and use |
| US6238931B1 (en) * | 1993-09-24 | 2001-05-29 | Biosite Diagnostics, Inc. | Fluorescence energy transfer in particles |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| JP2001514617A (ja) | 1997-01-21 | 2001-09-11 | ジ・アメリカン・ナショナル・レッド・クロス | 両親媒性フェノチアジン−５−イウム染料と光による全血および血液成分の細胞内および細胞外汚染除去 |
| US8267982B2 (en) * | 1998-08-25 | 2012-09-18 | Advanced Photodynamic Technologies, Inc. | Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| JP2000344685A (ja) | 1999-03-26 | 2000-12-12 | Bf Kenkyusho:Kk | アズールａ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物 |
| IT1307270B1 (it) | 1999-10-12 | 2001-10-30 | Dideco Spa | Procedimento e dispositivo per la determinazione della concentrazionedi eparina in un campione di fluido. |
| FR2810318B1 (fr) * | 2000-06-15 | 2005-09-23 | Laurent Galey | Derives de diamano-phenothiazine |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB2373787A (en) | 2001-03-08 | 2002-10-02 | Univ Central Lancashire | Phenothiazinium derivatives and their use to reduce pathogenic contaminants |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0113121D0 (en) | 2001-05-30 | 2001-07-18 | Univ Leeds | Biologically active photosensitisers |
| US7176308B2 (en) * | 2002-06-17 | 2007-02-13 | Verification Technologies, Inc. | Processes for preparing novel methylene blue derivative |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| AU2004295148A1 (en) * | 2003-11-28 | 2005-06-16 | Photopharmica Limited | Developments in biologically active methylene blue derivatives (2) |
| SI1799662T1 (sl) | 2004-09-23 | 2013-08-30 | Wista Laboratories Ltd. | Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC) |
| JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| CN104529939B (zh) | 2006-03-29 | 2019-05-07 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| DK3121169T3 (da) | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| WO2012107706A1 (en) | 2011-02-11 | 2012-08-16 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| SG11201900228YA (en) | 2016-07-25 | 2019-02-27 | Wista Lab Ltd | Administration and dosage of diaminophenothiazines |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| MX2021000894A (es) | 2018-07-26 | 2021-03-31 | Wista Lab Ltd | Dosificacion optimizada de diaminofenotiazinas en poblaciones. |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
-
2007
- 2007-07-10 DK DK16173815.8T patent/DK3121169T3/da active
- 2007-07-10 EP EP07733509.9A patent/EP2057136B1/en active Active
- 2007-07-10 EP EP16173815.8A patent/EP3121169B1/en active Active
- 2007-07-10 PL PL11173338T patent/PL2457905T3/pl unknown
- 2007-07-10 WO PCT/GB2007/002570 patent/WO2008007074A2/en not_active Ceased
- 2007-07-10 US US12/373,216 patent/US7956183B2/en active Active
- 2007-07-10 PL PL07733509T patent/PL2057136T3/pl unknown
- 2007-07-10 SI SI200731284T patent/SI2057136T1/sl unknown
- 2007-07-10 CN CN2007800336078A patent/CN101511803B/zh active Active
- 2007-07-10 PL PL11173334T patent/PL2457904T3/pl unknown
- 2007-07-10 DK DK11173338.2T patent/DK2457905T3/en active
- 2007-07-10 SI SI200731836A patent/SI2457905T1/sl unknown
- 2007-07-10 CN CN201210195299.1A patent/CN102718730B/zh active Active
- 2007-07-10 PT PT111733341T patent/PT2457904E/pt unknown
- 2007-07-10 JP JP2009518955A patent/JP5350237B2/ja active Active
- 2007-07-10 CA CA2657352A patent/CA2657352C/en active Active
- 2007-07-10 PT PT77335099T patent/PT2057136E/pt unknown
- 2007-07-10 PT PT111733382T patent/PT2457905T/pt unknown
- 2007-07-10 EP EP22153513.1A patent/EP4063354A1/en active Pending
- 2007-07-10 PL PL16173815T patent/PL3121169T3/pl unknown
- 2007-07-10 EP EP11173334.1A patent/EP2457904B1/en active Active
- 2007-07-10 PT PT161738158T patent/PT3121169T/pt unknown
- 2007-07-10 ES ES07733509T patent/ES2421930T3/es active Active
- 2007-07-10 HU HUE11173338A patent/HUE030621T2/en unknown
- 2007-07-10 LT LTEP11173338.2T patent/LT2457905T/lt unknown
- 2007-07-10 ES ES11173338.2T patent/ES2603783T3/es active Active
- 2007-07-10 SI SI200732186T patent/SI3121169T1/sl unknown
- 2007-07-10 ES ES11173334.1T patent/ES2529714T3/es active Active
- 2007-07-10 MY MYPI20090099A patent/MY148145A/en unknown
- 2007-07-10 MY MYPI2012001462A patent/MY162313A/en unknown
- 2007-07-10 SI SI200731596T patent/SI2457904T1/sl unknown
- 2007-07-10 ES ES16173815T patent/ES2912571T3/es active Active
- 2007-07-10 AU AU2007274057A patent/AU2007274057B2/en active Active
- 2007-07-10 EP EP11173338.2A patent/EP2457905B1/en active Active
- 2007-07-10 DK DK11173334.1T patent/DK2457904T3/en active
- 2007-07-10 DK DK07733509.9T patent/DK2057136T3/da active
-
2011
- 2011-05-31 US US13/149,164 patent/US8440821B2/en active Active
-
2013
- 2013-05-09 US US13/890,607 patent/US9382220B2/en active Active
- 2013-08-21 JP JP2013171087A patent/JP6243659B2/ja active Active
-
2016
- 2016-06-17 US US15/185,803 patent/US9675621B2/en active Active
- 2016-11-03 CY CY20161101128T patent/CY1118184T1/el unknown
-
2017
- 2017-06-09 US US15/619,199 patent/US9980971B2/en active Active
-
2018
- 2018-05-23 US US15/987,354 patent/US10525061B2/en active Active
-
2019
- 2019-11-15 US US16/685,420 patent/US11045477B2/en active Active
-
2021
- 2021-06-23 US US17/355,336 patent/US11878021B2/en active Active
-
2023
- 2023-12-08 US US18/533,515 patent/US20240115580A1/en not_active Abandoned
-
2025
- 2025-01-08 US US19/013,969 patent/US20250222006A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118184T1 (el) | Μεθοδοι συνθεσης και/ή καθαρισμου ενωσεων διαμινοφαινοθειαζινιου | |
| CY1114356T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| EA200501890A1 (ru) | Вирусы гриппа высокого титра для приготовления вакцин и генной терапии | |
| CY1107146T1 (el) | Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad) | |
| CY1121639T1 (el) | Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων | |
| CY1113560T1 (el) | Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων | |
| CY1121310T1 (el) | Χρηση πυριτικου ζιρκονιου για τη θεραπεια της υπερκαλιαιμιας | |
| CY1110665T1 (el) | Αναστολεις hiv ιντεγκρασης | |
| EA200601239A1 (ru) | Замещённые хинолиновые соединения | |
| SE0104140D0 (sv) | Novel Compounds | |
| EA201001273A1 (ru) | Ингибиторы вируса гепатита с | |
| CY1110266T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της hiv ιντεγκρασης | |
| CY1110318T1 (el) | Παραγωγα φαινοξυοξικου οξεος | |
| ATE478082T1 (de) | Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| DE602006019629D1 (de) | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna | |
| ATE546456T1 (de) | Triheterocyclische verbindungen, zusammensetzungen, und verfahren zur behandlung von krebs | |
| CY1107911T1 (el) | Διαταξη αφαιρεσεως | |
| CY1111275T1 (el) | Κρυσταλλικη μορφη μιας ενωσης κινολινονης-καρβοξαμιδιου | |
| EA201101674A1 (ru) | 2,4-диаминопиримидины, предназначенные для лечения заболеваний, характеризующихся избыточной или аномальной пролиферацией клеток | |
| CY1108366T1 (el) | Βενζοσουλφονικο αλας της 7-(2-(4-(3-τριφθορομεθυλ-φαινυλ-1,2,3,6-τετραϋδρο-πυριδ-1-υλ)αιθυλ)ισοκινολινης, η παρασκευη του και η χρηση του στη φαρμακευτικη αγωγη | |
| DE602006020152D1 (de) | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion | |
| NO20050088L (no) | Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav | |
| EA200901412A1 (ru) | Замещенные индолы, способ их получения и применения | |
| NO20073839L (no) | Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette |